Press

R&D investment in the biotech sector grows by 5.2% to 1,282 million euros

11/06/2025

Healthcare · Agrifood · Industrial biotechnology · Financing · Talento

• In 2023, the activity of biotech companies in Spain generated more than 13,000 million euros of income, which represents 1.1% of the national GDP.
• After an exceptional 2023 for the sector in terms of attracting investment, in 2024 it raised a total of 181 million euros in 53 operations.
• The number of biotech companies in Spain grew in 2024 to 1,014 companies, an increase of 4.1% over the previous year.
• Once again this year, biotech companies maintain the second position in the ranking of sectors with the highest percentage of researchers over total employees with 15.99%.

AseBio

World Multiple Sclerosis Day | “The integration of biotechnology and AI allows us to move towards increasingly precise and timely treatments”

30/05/2025

Healthcare · Personalized medicine · Advanced therapies

• Interview with Mireia Forner, Medical Head of Neurology at Sanofi Iberia, a company working to change how multiple sclerosis is understood and treated.
• Each year, more than 2,500 new cases of multiple sclerosis (MS) are diagnosed in Spain, and as of 2024, over 55,000 people were living with this autoimmune disease.
• “Biotechnological development will allow us to adapt treatment to the unique characteristics of each person and detect signs of progression even before they become clinically evident.”

AseBio

AseBio strengthens the strategic role of the biotechnology sector in the National Forum for Emerging Companies

29/05/2025

Industrial biotechnology · Financing

• This space, created at the end of last year by the Government, is intended as a space for dialogue and collaboration between the public sector and the Spanish entrepreneurial ecosystem, driven by the "Startups Law."
• AseBio stands as the only sectoral organization represented in this body, alongside the digital sector, highlighting the recognition of biotechnology as a strategic sector within the field of emerging companies.
• The "Startups Law," enacted in 2022, incorporated proposals from AseBio, such as extending the period for considering biotech companies as startups from five to seven years, and expanding the tax deduction base for investments in newly created companies.

AseBio

The essential role of biotechnology in the production of safe, nutritious, and sustainable food

28/05/2025

Climate change · Agrifood · Food & feed · Agriculture

• Over 800 million people suffer from chronic hunger, and biotechnology is revolutionizing the way we produce food, offering more sustainable and efficient alternatives.
• In the face of hunger challenges, biotechnological innovation opens new opportunities: insect-based proteins, more resilient crops, predictive biostimulants, and digital solutions for more precise and regenerative agriculture.
• AseBio partners are leading the shift towards a more sustainable agri-food system, combining biotechnology, artificial intelligence, and regenerative practices to ensure safe and affordable food for all.

AseBio

International Clinical Trials Day: Driving healthcare innovation through Artificial Intelligence

20/05/2025

Healthcare · Access to innovation · Digitalization

• Spain positions itself as a European leader in clinical trials, while facing challenges such as improving clinical data coding and increasing investment in R&D.
• The TerminAI project aims to optimize healthcare data management through artificial intelligence, enhancing the efficiency and accuracy of clinical information coding.
• This project is being developed by a consortium led by the Basque Health Cluster and composed of NorayBio, BIOLAN, Vicomtech, EProcessMed, AseBio, and the start-up Devol, under the Ministry of Industry and Tourism’s support program for innovative business clusters.

AseBio

Biomedical innovation 'made in Spain': Challenges and opportunities in the long race to market

13/05/2025

Healthcare · Access to innovation · Financing

• Experts from the sector highlighted at the 18th Annual Conference of the Biomedical Research Technology Platforms the need to promote effective mechanisms for support, funding, and collaboration to transform scientific knowledge into real solutions for patients.
• Although Spain has a solid biomedical ecosystem and holds a prominent position in clinical trials, it still faces major challenges in bringing innovations to market.
• Strengthening public-private collaboration, boosting investment, and developing a mature business ecosystem capable of competing globally remain key challenges for Spain.
   

AseBio

BIOSPAIN 2025: The Role of the Biotechnology Industry in the EU’s Strategic Autonomy

25/04/2025

BioSpain

• Europe’s ability to develop biotech solutions is crucial to securing its economic and strategic future.
• Under the motto “Global crossroads, local vibes”, the event aims to connect local talent with European and American ecosystems.
• BIOSPAIN 2025 will feature the Green Innovation Forum, a dedicated space for companies in the agricultural, food, and industrial biotechnology sectors.
   

AseBio

Biotechnology emerges as the great ally in the face of the climate crisis

26/03/2025

Climate change · Agrifood · Food & feed · Agriculture · Bioeconomy · Circular economy

• Biotechnology has consolidated itself as a strategic tool to combat climate change, driving innovation in sectors such as agriculture, energy, and industry.
• Innovative solutions like bioenergy production, chemical recycling of plastics, and the use of microalgae are transforming key sectors.
• Thanks to biotechnology research and development, it is possible to move toward a greener and more resilient economic model.
   

AseBio

Biotechnology advances in the development of key therapies for kidney diseases

13/03/2025

• It is estimated that chronic kidney disease (CKD) affects approximately 850 million people worldwide.
• World Kidney Day highlights that implementing global early detection policies is crucial to reduce healthcare costs associated with kidney failure and improve patients’ quality of life.
• By 2040, CKD is projected to become the fifth leading cause of years of life lost, emphasizing the urgent need for global strategies to combat this disease.
   

AseBio